These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
847 related articles for article (PubMed ID: 22915548)
1. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization. Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548 [TBL] [Abstract][Full Text] [Related]
2. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195 [TBL] [Abstract][Full Text] [Related]
3. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation. Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609 [TBL] [Abstract][Full Text] [Related]
4. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450 [TBL] [Abstract][Full Text] [Related]
5. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity. Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458 [TBL] [Abstract][Full Text] [Related]
6. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826 [TBL] [Abstract][Full Text] [Related]
7. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery. Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361 [TBL] [Abstract][Full Text] [Related]
8. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Vandiver JW; Vondracek TG Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756 [TBL] [Abstract][Full Text] [Related]
9. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506 [TBL] [Abstract][Full Text] [Related]
10. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070 [TBL] [Abstract][Full Text] [Related]
11. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study. Naumnik B; Pawlak K; Myśliwiec M Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290 [TBL] [Abstract][Full Text] [Related]
12. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women. Bombeli T; Raddatz-Mueller P; Fehr J Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491 [TBL] [Abstract][Full Text] [Related]
13. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010 [TBL] [Abstract][Full Text] [Related]
14. The PiCT Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411 [TBL] [Abstract][Full Text] [Related]
15. Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study. Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C J Thromb Haemost; 2017 Jan; 15(1):38-46. PubMed ID: 27736032 [TBL] [Abstract][Full Text] [Related]
16. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement. Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174 [TBL] [Abstract][Full Text] [Related]
17. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756 [TBL] [Abstract][Full Text] [Related]
18. In vivo age dependency of unfractionated heparin in infants and children. Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072 [TBL] [Abstract][Full Text] [Related]
19. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357 [TBL] [Abstract][Full Text] [Related]
20. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]